Analysts forecast that Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) will report earnings of ($0.05) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Eyegate Pharmaceuticals’ earnings. Eyegate Pharmaceuticals reported earnings per share of ($0.07) in the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The firm is scheduled to announce its next earnings report on Friday, August 16th.
On average, analysts expect that Eyegate Pharmaceuticals will report full-year earnings of ($0.13) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will post earnings of ($0.23) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Eyegate Pharmaceuticals.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01.
In other news, insider Stephen From sold 127,355 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $0.24, for a total transaction of $30,565.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 166,154 shares of company stock worth $39,877 over the last three months. Corporate insiders own 47.50% of the company’s stock.
NASDAQ EYEG remained flat at $$0.20 during trading hours on Tuesday. The company’s stock had a trading volume of 163,959 shares, compared to its average volume of 350,569. The firm has a market capitalization of $9.57 million, a P/E ratio of -0.68 and a beta of 2.04. Eyegate Pharmaceuticals has a 1 year low of $0.20 and a 1 year high of $0.64. The stock has a fifty day moving average price of $0.23.
Eyegate Pharmaceuticals Company Profile
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Read More: What is systematic risk?
Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.